To imagine the impossible,
takes both brilliant minds and a vision.

We’re proud to say our team is made up of just that — people and minds both driven by passion
and full of potential. Our company is led by a team of executives and directors with vast experience
and proven track records in pain, drug development and commercialization.

 
 

Executive Management team

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

“Turning a ship in a storm is never easy. We have been weathering the opioid crisis and will soon have the wind behind us!”
 
“As crisis and consolidation occur in the opioid sector, Ensysce is positioned to become both best in class and market leader in abuse deterrence through safety efficacy and competitive pricing to generics.”
RW_photo.png

RICHARD WRIGHT, MSE, MBA

Chief Business Officer

 

KURT SCHMIDT, MBA

Chief Financial Officer

“Lorem ipsum dolor sit amet, est vocent iracundia ut, augue.”
 
“Being able to protect against opioid overdose – using MPAR technology – is a disruptive technology that will set Ensysce apart from all other conventional and abuse-deterrent opioid products.”
WS_photo.png

WILLIAM SCHMIDT, PHD

Chief Medical Officer

 

GEOFF BIRKETT

Chief Commercial Officer

“We are in a war against opioids. We need to change the rules of engagement. Formulations haven’t worked so we went back to basic chemistry.”
 
“Sed purus sem, scelerisque ac rhoncus eget, porttitor nec odio. Lorem ipsum dolor sit amet.”
JM_photo.png

JEFFREY MILLARD, PHD

Chief Operating Officer

 
 
 
 
 

D. Lynn Kirkpatrick, PHD

Dr. Kirkpatrick has focused her entire career on drug discovery and development. Former Professor of Chemistry and Biochemistry in Canada, she has co-founded two start up companies and successfully brought three novel cancer drug candidates into human clinical trails. Following the acquisition of her first company, by Biomira Inc., (Oncothyreon) in 2006, Dr. Kirkpatrick took the role as the Chief Scientific Officer of the merged company. She became President and CEO of Ensysce Biosciences Inc. in January 2009. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and completed a post-doctoral fellowship at Yale University School of Medicine. She has published extensively in the area of targeted drug discovery and development and holds numerous patents for novel targeted drugs and delivery technology.

Executive Management team

 

Hello, World!

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

D. LYNN KIRKPATRICK, PHD

“Turning a ship in a storm is never easy. We will soon have the wind behind us!”
 

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

 
“Richard’s quote to go here… Lorem ipsum dolor sit amet, est vocent iracundia ut, augue”

D. LYNN KIRKPATRICK, PHD

Chief Executive Officer

RICHARD WRIGHT, MSE, MBA

Chief Business Officer

 

KURT SCHMIDT, MBA

Chief Financial Officer

“Lorem ipsum dolor sit amet, est vocent iracundia ut, augue.”
 
“Vivamus pellentesque vitae neque at vestibulum.
Donec efficitur mollis dui vel pharetra.”
WS_photo_round.png

WILLIAM SCHMIDT, PHD

Chief Medical Officer

 

GEOFF BIRKETT

Chief Commercial Officer

“We are in a war against opioids. We need to change the rules of engagement. Formulations haven’t worked so we went back to basic chemistry.”
 
“Sed purus sem, scelerisque ac rhoncus eget, porttitor nec odio. Lorem ipsum dolor sit amet.”
JM_photo_round.png

JEFFREY MILLARD, PHD

Chief Operating Officer